Since a therapy has not been yet developed for mitochondrial diseases caused by POLG mutations, a major goal of the research involving yeast/animal models is to find new strategies to rescue the pathological phenotypes associated to these mutations. This evidence concerns the gene POLG and inborn mitochondrial metabolism disorder.